Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications ...
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company is dedicated to addressing serious diseases where current treatments are inadequate, aiming to alter the underlying pathological pathways rather than just ...Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company is dedicated to addressing serious diseases where current treatments are inadequate, aiming to alter the underlying pathological pathways rather than just managing symptoms. Contineum's lead product candidate is PIPE-791, a brain-penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R), which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and chronic pain. Additionally, the company is advancing PIPE-307, a small molecule inhibitor of the muscarinic type 1 receptor (M1R), for the treatment of depression and relapsing-remitting multiple sclerosis (RRMS). Contineum has been strategically formed with support from Versant Ventures, initially as Pipeline Therapeutics, and changed its name to Contineum Therapeutics in November 2023. The company went public in April 2024 with an initial public offering (IPO) raising approximately $110 million, and has since maintained a strong financial position with a healthy balance sheet. As of the latest data, Contineum had 51 full-time employees, reflecting its lean operational structure typical of clinical-stage biotech firms. The company has not yet generated revenue, as it is in the development stage, and its financial metrics show negative profitability and cash flow from operations, which is common for biotech companies investing heavily in R&D. However, Contineum boasts a robust pipeline, strong scientific leadership, and a focus on clinically validated targets, positioning it for potential growth as its therapies advance through clinical trials. The company's management team, led by CEO Carmine N. Stengone, brings extensive experience in business development and science, aiming to drive the company toward commercialization and ultimately improve patient outcomes in NI&I diseases.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-60.0M
-41.9%
-4.8%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-55.5M
-66.5%
+30.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
3.2%
+0.0%
-1.4%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
27.50x
+32.9%
-2.2%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
